Ravulizumab-cwvz | Aplastic Anemia & MDS International Foundation

Ravulizumab-cwvz

Brand name: 
Ultomiris®
Bone Marrow Disease(s): 
paroxysmal nocturnal hemoglobinuria (PNH)

Ravulizumab-cwvz (Ultomiris®) is a drug approved by the U.S. Food and Drug Administration (FDA) in 2018 to treat PNH. ULTOMIRIS® is a long-acting C5 inhibitor that works by inhibiting the C5 protein in the terminal complement cascade.

ULTOMIRIS® is a prescription medicine called a monoclonal antibody. ULTOMIRIS® is used to treat adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). It is not known if ULTOMIRIS® is safe and effective in children. ULTOMIRIS® is a long-acting C5 inhibitor administered every eight weeks that works by inhibiting the C5 protein in the terminal complement cascade.

ULTOMIRIS® increases your chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early.

For more information, please see the therapy page about this drug.

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.